Skip to main content

Table 2 Clinical outcomes at 90 days and 1 year

From: The impact of stress hyperglycemia ratio on short-term and long-term outcomes for acute basilar artery occlusion underwent endovascular treatment

SHR levels

Frequencies

Crude Model

Model 1a

Model 2b

Model 3c

Unadjusted OR (95% CI)

P value

Adjusted OR (95% CI)

P value

Adjusted OR (95% CI)

P value

Adjusted OR (95% CI)

P value

90 days

 mRS score of 0–3, No. (%)

  T1 (≤ 1.11)

48 (57.8)

Reference

 

Reference

 

Reference

 

Reference

 

  T2 (1.12–1.36)

24 (28.9)

0.30 (0.16–0.57)

 < 0.001

0.26 (0.12–0.56)

0.001

0.25 (0.11–0.55)

0.001

0.25 (0.11–0.56)

0.001

  T3 (≥ 1.37)

29 (34.5)

0.38 (0.21–0.72)

0.003

0.37 (0.18–0.80)

0.01

0.37 (0.17–0.80)

0.01

0.33 (0.15–0.74)

0.007

  P for trend

  

0.004

 

0.01

 

0.01

 

0.01

 mRS score at 90 days, median (IQR)*

  T1 (≤ 1.11)

3 (1–6)

Reference

 

Reference

 

Reference

 

Reference

 

  T2 (1.12–1.36)

5 (2–6)

0.42 (0.24–0.72)

0.002

0.45 (0.26–0.79)

0.006

0.44 (0.25–0.79)

0.006

0.45 (0.25–0.82)

0.009

  T3 (≥ 1.37)

5 (2–6)

0.44 (0.25–0.76)

0.003

0.54 (0.31–0.96)

0.04

0.57 (0.32–1.01)

0.054

0.45 (0.25–0.82)

0.009

  P for trend

  

0.005

 

0.046

 

0.07

 

0.01

 Mortality, No. (%)

  T1 (≤ 1.11)

22 (26.5)

Reference

 

Reference

 

Reference

 

Reference

 

  T2 (1.12–1.36)

33 (39.8)

1.83 (0.95–3.53)

0.07

1.68 (0.82–3.44)

0.15

1.81 (0.87–3.75)

0.11

1.89 (0.83–4.32)

0.13

  T3 (≥ 1.37)

34 (40.5)

1.89 (0.98–3.63)

0.06

1.59 (0.78–3.25)

0.20

1.54 (0.74–3.17)

0.25

2.14 (0.95–4.83)

0.07

  P for trend

  

0.07

 

0.24

 

0.30

 

0.08

1 year

 mRS score of 0–3, No. (%)

  T1 (≤ 1.11)

46 (59.0)

Reference

 

Reference

 

Reference

 

Reference

 

  T2 (1.12–1.36)

27 (34.6)

0.37 (0.19–0.71)

0.003

0.34 (0.16–0.73)

0.006

0.36 (0.16–0.77)

0.009

0.37 (0.17–0.85)

0.02

  T3 (≥ 1.37)

28 (35.9)

0.39 (0.20–0.74)

0.004

0.38 (0.18–0.82)

0.01

0.41 (0.19–0.88)

0.02

0.37 (0.16–0.82)

0.02

  P for trend

  

0.006

 

0.02

 

0.03

 

0.02

 mRS score at 1 year, median (IQR)†

  T1 (≤ 1.11)

3 (0–6)

Reference

 

Reference

 

Reference

 

Reference

 

  T2 (1.12–1.36)

6 (2–6)

0.41 (0.23–0.73)

0.003

0.44 (0.24–0.81)

0.009

0.45 (0.24–0.84)

0.01

0.49 (0.26–0.93)

0.03

  T3 (≥ 1.37)

5 (2–6)

0.46 (0.26–0.82)

0.008

0.60 (0.33–1.10)

0.10

0.63 (0.34–1.17)

0.14

0.53 (0.28–1.00)

0.05

  P for trend

  

0.01

 

0.12

 

0.17

 

0.06

 Mortality, No. (%)

  T1 (≤ 1.11)

27 (34.6)

Reference

 

Reference

 

Reference

 

Reference

 

  T2 (1.12–1.36)

41 (52.6)

2.09 (1.10–3.99)

0.03

1.95 (0.97–3.93)

0.06

1.84 (0.90–3.75)

0.09

1.75 (0.80–3.81)

0.16

  T3 (≥ 1.37)

38 (48.7)

1.79 (0.94–3.42)

0.08

1.52 (0.76–3.05)

0.24

1.42 (0.70–2.88)

0.34

1.73 (0.80–3.73)

0.16

  P for trend

  

0.10

 

0.29

 

0.39

 

0.19

  1. Abbreviations: mRS Modified Rankin Scale, SHR Stress hyperglycemia ratio, OR Odds ratio, CI Confidence interval
  2. *P value for odds propotional assumption was 0.28 for mRS score at 90 days
  3. †P value for odds propotional assumption was 0.20 for mRS score at 1 year
  4. aModel 1 adjusted for age, baseline NIHSS, stroke etiology and occlusion site
  5. bModel 2 adjusted for covariates from Model 1and further adjusted for history of diabetes mellitus and intravenous thrombolysis status
  6. cModel 3 adjusted for covariates from Model 2 and further adjusted for sex and successful recanalization
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us